Compare PRAX & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRAX | LBRDK |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Cable & Other Pay Television Services |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 6.4B |
| IPO Year | 2020 | N/A |
| Metric | PRAX | LBRDK |
|---|---|---|
| Price | $299.14 | $49.32 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $572.13 | N/A |
| AVG Volume (30 Days) | 309.6K | ★ 960.6K |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6,395.88 | $109.28 |
| P/E Ratio | ★ N/A | $10.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.70 | $42.10 |
| 52 Week High | $354.87 | $104.00 |
| Indicator | PRAX | LBRDK |
|---|---|---|
| Relative Strength Index (RSI) | 43.28 | 43.35 |
| Support Level | $290.36 | $47.49 |
| Resistance Level | $322.32 | $50.21 |
| Average True Range (ATR) | 16.93 | 1.75 |
| MACD | -3.50 | -0.58 |
| Stochastic Oscillator | 22.92 | 17.40 |
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.